Search – Page 213 – Indianapolis Business Journal

Home » Search

Articles

Business elite back alternative high school: Catholic college-prep Cristo Rey puts students to work to earn and learn

January 15, 2007

Every other month, it seems, someone announces another promising alternative to the city’s public schools and their low achievement levels and high dropout rates. If it isn’t Indianapolis Public Schools announcing another specialty school within a high school, it’s a new charter school anointed by Mayor Bart Peterson-a number now approaching 20. So one could be forgiven for being a bit cynical about these schools, as parents who can afford to continue to leave the city for better schools. But…

Anti-clotting prospect most important for Lilly, report says

January 12, 2007

A drug Eli Lilly and Co. is developing to prevent blood clots is the most important in Lilly’s pipeline, according to a report on TheStreet.com this morning. Prasugrel, which aims to prevent heart attacks and strokes, faces important clinical trials this year, and could yield several billion dollars in sales. However, its impact on the […]

Lilly says Zyprexa settlement cost $495 million

January 11, 2007

Eli Lilly and Co. revealed in a regulatory filing today that the recent settlement of a Zyprexa class-action lawsuit cost $495 million, according to Bloomberg. The Indianapolis pharmaceutical company announced Jan. 4 that it had reached the agreement on 18,000 claims, leaving 1,200 remaining to resolve. The plaintiffs claimed the drug caused them to gain […]

Lilly to invest in Indy, cut Lafayette work force

January 11, 2007

Eli Lilly and Co. said today it will invest “significant resources” in biotechnology manufacturing in Indianapolis and offer voluntary buyouts to 250 workers in Lafayette as part of a shake-up of global manufacturing operations. The Indianapolis drug maker said it will expand Indianapolis operations in order to turn active ingredients made at an expanded site […]

Judge orders Zyprexa link pulled from Web site

January 10, 2007

A federal judge in New York has ordered a Web site to take down a link to internal Eli Lilly and Co. documents about its controversial schizophrenia drug Zyprexa. The documents posted on Zyprexa.pbwiki.com were the basis of recent stories in The New York Times suggesting the Indianapolis drug maker downplayed weight gain and other […]

Major Icos shareholder to vote against Lilly offer

January 9, 2007

HealthCor Management, which owns 5.2 percent of Icos Corp., said Monday it will vote against Eli Lilly and Co.’s sweetened offer of $34 per share for the maker of the erectile dysfunction drug Cialis. HealthCor complained that Lilly’s second offer doesn’t compensate for improved financial projections for the Bothell, Wash., company, according to The Seattle […]

Lilly funds second factory line for inhaled insulin

January 8, 2007

Eli Lilly and Co. has agreed to fund a second manufacturing line at an Alkeres Inc. plant to make its Inhaled Insulin System powder. Lilly’s system, to be marketed as an alternative for types 1 and 2 diabetes, is in phase 3 clinical trials. The deal also makes Cambridge, Mass.-based Alkeres the exclusive manufacturer of […]

Father-son team caters to wealthy clientele: Goelzer a local fixture in portfolio management

January 8, 2007

Reeling in 45-inch northern pike during annual fishing excursions to the upper regions of Canada is one type of bonding experience Don and Greg Goelzer cherish. But the camaraderie the father and son share really is rooted in the 25 years they have spent working side by side at Goelzer Investment Management Inc., the downtown advisory firm Don founded in 1969. In the quarter-century since son Greg arrived fresh from college, the two have helped grow the firm’s client base…

Lilly licenses British diabetes technology

January 5, 2007

Eli Lilly and Co. said this morning that it has licensed rights to the diabetes and obesity subsidiary of Melville, N.Y.-based OSI Pharmaceuticals Inc. for $25 million plus as much as $360 million in addition payments, depending on the success of any compounds developed through the arrangement. The subsidiary, Prosidion Limited, is in the United […]

Lilly settles most remaining Zyprexa claims

January 4, 2007

Eli Lilly and Co. has agreed to settle most of the remaining liability claims against its Zyprexa schizophrenia drug, the Indianapolis drug maker announced this morning. The agreement covers about 18,000 people. Lilly did not disclose the cost of the settlement, but said the total amount is “substantially less” than the $700 million it […]

Ariad patent victory over Lilly among largest in 2006

January 3, 2007

Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals
Inc. went down as the 6^th-largest such jury award last year, a Bloomberg analysis shows.

CICP’s chief launches raft of initiatives:

January 1, 2007

In January, Mark Miles returned to Indianapolis after more than a decade at the helm of the Association of Tennis Professionals to become CEO of the Central Indiana Corporate Partnership. Twelve months later, the CICP looks much different than it did under his predecessor David Goodrich. And it could soon change even more. A former Eli Lilly and Co. executive and aide to Dan Quayle, Miles, 53, has been one of the key players in the potential consolidation of the…

Buyout frenzy hits Indiana firms:

January 1, 2007

The year closed with two multibilliondollar buyouts of Indiana public companies-Carmel-based Adesa Inc. and Warsaw-based Biomet Inc. It was a fitting way to wrap up what was a record year for U.S. buyouts, many of them launched by deep-pocketed private equity firms. Adesa, an operator of auto auctions, announced Dec. 22 that it will be sold to a group of private-equity investors, including New York-based Goldman Sachs Group Inc., for $3.7 billion. Four days earlier, Biomet, a maker of orthopedic…

For Cornelius ’06 was full of challenges:

January 1, 2007

Long-time Indianapolis business leader Jim Cornelius jumped from one daunting challenge to another in 2006. He started the year as chairman and CEO of Guidant Corp., as it weighed a possible sale to either New Jer sey-based Johnson & Johnson or Massachusetts-based Boston Scientific Corp. After Boston Scientific won, Cornelius became acting CEO of New York-based Bristol-Myers Squibb Co. in September. Cornelius stayed with Guidant from start to finish. He left his position as chief financial officer at Eli Lilly…

Firearm advocates take aim at employers’ restrictions

December 25, 2006

Legislators in the upcoming session of the Indiana General Assembly are gearing up for a gunfight with high-caliber business
implications. On one side are employees who prefer to pack heat during their commute. On the other are executives who see
guns as a liability nightmare–even if they’re locked in cars parked outside.

Landing the young gains importance: How is a city to please 25- to 34-year-olds?

December 18, 2006

College-educated young adults should consider themselves lucky-everybody wants them. Cities nationwide are bending over backward trying to figure out what hip amenities will attract “the young and the restless.” Arts organizations are looking for ways to get them to performances. Even newspapers are getting into the act, launching specialty publications aimed directly at them. Why so much love? Time’s ticking. Baby boomers are getting older, and someone has to take their place as employees, taxpayers, arts patrons and news readers….

Complaints accuse Lilly of illegally marketing Zyprexa

December 11, 2006

Eli Lilly and Co. is facing another round of litigation over its star seller, Zyprexa, as insurers and third-party payers
ask to be reimbursed for covering the antipsychotic drug.

INVESTING: Drug stocks are out of favor-so snap up the bargains

December 11, 2006

One of the biggest companies in the world just dropped a bomb. Investors got scared. I am going to tell you why Wall Street took the news the wrong way, and what it means to one of the most important industries to consumers. In the 1990s, Pfizer made a series of acquisitions that transformed the company into the second-largest drug firm in the world. Pfizer is worth about three times Eli Lilly’s market value. Until now, Pfizer employed more than…

State’s venture capital incentive seldom used

November 27, 2006

Since the inception of the state’s Venture Capital Investment Tax Credit in late 2003, investors have claimed only about one-third of the $37.5 million in credits available, according to an IBJ analysis of the program.

CHRIS KATTERJOHN Commentary: Working together on multiple fronts

November 27, 2006

Nov. 14 was a good day for Indianapolis. It was the day we learned the Diversity Leadership Academy of Greater Indianapolis is alive and well. Three years ago, I attended the academy in the inaugural year of a three-year program that was brought here by Atlanta-based American Institute for Managing Diversity. What facilitated its arrival in 2003 was a three-year sponsorship to the tune of more than a half-million dollars by Anthem, a local company that has been at the…

« Previous 1 … 211 212 213 214 215 … 221 Next »

Search Results

4,410 results for '\"eli lilly\"'

Articles

Business elite back alternative high school: Catholic college-prep Cristo Rey puts students to work to earn and learn

Anti-clotting prospect most important for Lilly, report says

Lilly says Zyprexa settlement cost $495 million

Lilly to invest in Indy, cut Lafayette work force

Judge orders Zyprexa link pulled from Web site

Major Icos shareholder to vote against Lilly offer

Lilly funds second factory line for inhaled insulin

Father-son team caters to wealthy clientele: Goelzer a local fixture in portfolio management

Lilly licenses British diabetes technology

Lilly settles most remaining Zyprexa claims

Ariad patent victory over Lilly among largest in 2006

CICP’s chief launches raft of initiatives:

Buyout frenzy hits Indiana firms:

For Cornelius ’06 was full of challenges:

Firearm advocates take aim at employers’ restrictions

Landing the young gains importance: How is a city to please 25- to 34-year-olds?

Complaints accuse Lilly of illegally marketing Zyprexa

INVESTING: Drug stocks are out of favor-so snap up the bargains

State’s venture capital incentive seldom used

CHRIS KATTERJOHN Commentary: Working together on multiple fronts